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domain, a G protein -like (GGL) domain, and the cata-
lytic core RGS domain (Figure 1). The functions of the
DEP and I are not completely understood, although there
is evidence supporting a role in membrane targeting,
and the GGL domain mediates specific interaction with
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tional modifications give rise to over a dozen different
proteins. For example, a brain-specific isoform of RGS9,
RGS9-2, has aroused particular interest because its ex-RGS proteins act as negative regulators of G protein
pression is largely restricted to the dorsal and ventralsignaling, and there is growing evidence that the RGS
striatum, which receive most of the inputs to the basalfamily is important for regulating signaling in neurons.
ganglia. RGS9-2 is expressed in the medium spiny cells,Two articles in this issue of Neuron (Martemyanov et
upon which many neuromodulatory afferents convergeal. and Rahman et al.) shed light on the function of
to control the output to the globus pallidus and substan-one family member, RGS9-2, in behavioral responses
tia nigra (reviewed in Greengard, 2001; Calabresi et al.,to dopamine signaling in the striatum and on the rela-
2000). Despite the fact that the anatomical and physio-tionship between its structure and its function.
logical properties of these neurons within the circuitry
of the basal ganglia are fairly well understood, the impor-In recent years, RGS (Regulators of G protein Signaling)
tance of terminating G protein signaling rapidly—andproteins have emerged as key components in regulation
thus the specific role of RGS9-2 in these cells—remainsof cellular responses to extracellular signals acting
unknown. Two papers in this issue of Neuron (Martemy-through G protein-coupled receptors (reviewed in Hol-
anov et al., 2003 and Rahman et al., 2003) provide newlinger and Hepler, 2002). The RGS domains of this di-
clues to the function and regulation of RGS9-2. Readersverse family, encoded by close to 30 genes in mammals,
interested in the previously published work on RGS9-1bind to  subunits of heterotrimeric G proteins and ac-
and RGS9-2 are referred to the citations in these twocelerate their hydrolysis of GTP, thus speeding their
papers, including RGS9-specific reviews (e.g., Arshav-return to the inactive state and terminating or attenuat-
sky et al., 2002; Cowan et al., 2001).ing downstream responses. They serve as GTPase Ac-
Much about the structure and function of RGS9-2celerating Proteins, or GAPs. Although many neuromod-
has been learned by comparison to the biochemicalulators are generally considered to be slow acting, the
properties of RGS9-1 (Figure 1B). Like RGS9-1, RGS9-2abundance of some members of the RGS family in the
also contains a GGL domain, which mediates its interac-nervous system suggests that neurons commonly re-
tion with G5S, a splice variant of the G5 gene expressedquire temporal regulation of intracellular G protein sig-
in brain. The association of RGS9-2 with G5 is importantnaling. Although RGS proteins are differentially ex-
for the stability and GAP activity of the complex, similarpressed in region-specific patterns in the mammalian
to the effects of G5L on RGS9-1. One of the more in-brain, defining the precise physiological roles of individ-
triguing features of RGS9-1 is its regulation by the 
ual RGS proteins in neurons has, with a few notable
subunit of the effector enzyme cGMP phosphodiester-
exceptions, remained an elusive problem. ase (PDE6), which is activated by RGS9-1’s target G
One exception has been RGS9-1, one of two products protein transducin (Gt). The Gt complex with PDE is aof the RGS9 gene. Its role as the regulator of G protein much better (lower Km) substrate for RGS9-1 than isinactivation kinetics during the recovery phase of light the G protein itself. The mechanism for this effect is
responses in rods and cones has been firmly established complex; mutagenesis studies with full-length and trun-
by a combination of biochemical and physiological ex- cated forms of RGS9-1 reveal that its multiple domains,
periments with wild-type and knockout animals. Under- as well as its obligate binding partner G5, all play impor-
standing the physiological function of RGS9-1 in photo- tant roles in the regulation by PDE. The domains impor-
receptors has facilitated studies of its regulation and tant for stimulation of RGS9-1’s GAP activity by PDE
led to the discovery of its interaction with other signal include the short, distal C-terminal domain of RGS9-1
transducing proteins besides its target Gt, including its that is absent in the brain isoform RGS9-2. RGS9-2 has
obligate binding partner G5, an anchor protein R9AP, instead a completely different and much longer C-ter-
a cGMP phosphodiesterase inhibitory subunit, PDE6, minal domain (Figure 1), for which until recently there
and protein kinase C. were no functions known.
RGS9-1 is a member of the R7 (or C) family of RGS These observations have raised the question of how
proteins, which share a common multidomain structure RGS9-2 can serve as an effective GAP for its target
(Zhong and Neubig, 2001; Cowan et al., 2001) including, G protein(s) in the absence of PDE. Traces of PDE
near the N terminus, a DEP domain, an intervening or I expression have been found in other tissues such as
lung, but none so far in the striatum where RGS9-2
expression is largely confined. A partial answer to this*Correspondence: twensel@bcm.tmc.edu
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Figure 1. Domain Structure of RGS9-1 and
RGS9-2
question is provided by recent results from Vadim Ar- a profound circling toward the side with RGS9-2 overex-
pression when the rats were administered dopamineshavsky and colleagues (Martemyanov et al., 2003).
They noticed sequence similarity between part of the receptor (specifically D2) agonists. This circling behavior
is thought to arise from an imbalance in dopaminergicC-terminal tail of RGS9-2 and PDE and decided to test
the hypothesis that this domain increases RGS9-2 GAP signaling, consistent with the overexpression of RGS9-2
decreasing the sensitivity to dopamine. Rats overex-activity, analogous to the effect of PDE on RGS9-1. The
results suggest that indeed it does. In the presence pressing RGS9-2 bilaterally showed less sensitivity to
moderate doses of cocaine, as assayed by a reduction inof the PDE-like stretch in its C-terminal tail, RGS9-2
displays high GAP activity, just as RGS9-1 does in the cocaine-induced locomotor activity. Conversely, RGS9
knockout mice show enhanced locomotor activity,presence of PDE. Addition of PDE does not stimulate
GAP activity further, but instead inhibits it, presumably greater sensitization, and greater place conditioning in
response to cocaine. Together, these results are consis-by competing with RGS9-2’s C-terminal tail. When GAP
activity was tested for a truncated form of RGS9-2 lack- tent with the notion that RGS9-2 turns down the re-
sponse to dopamine in the nucleus accumbens.ing the C-terminal 45 amino acids, including a stretch
of six identical to a sequence in PDE, the activity was The results from Nestler’s group imply a role for
RGS9-2 in signaling from D2 dopamine receptors, butsignificantly reduced. Taken together, these observa-
tions seem to be yet another example of a principle it is too early to say whether the effects they observe
are the result of direct action on G proteins activatedpointed out in genome-scale studies from David Eisen-
berg and colleagues: pairs of proteins homologous to directly by D2 receptors or the result of a more complex
network of interactions (Figure 2). Because RGS9-2 doespairs of domains found covalently attached in multido-
main proteins are very often functional interaction part- not need to rely on an effector molecule to enhance
GTP hydrolysis (see above), it remains unknown howners (Marcotte et al., 1999). As pointed out by Martemya-
nov et al., one function of such interaction partners can and if the action of RGS9-2 is cascade specific. Answer-
ing these questions will require knowing which G pro-be to act as “affinity adapters” to control specificity
of interactions with additional proteins. However, the teins and effectors, operating in response to which G
protein-coupled receptors, are regulated by RGS9-2.details of the interactions seem to be somewhat different
in the two cases compared here. Six consecutive resi- Localization of RGS9-1 in rod outer segments where
dues in PDE are known by crystallography to contact
G in the G-RGS-PDE complex (Slep et al., 2001), and
mutating one of them, Trp70, causes complete loss of
the ability to stimulate GAP activity (Slepak et al., 1995).
Changing all six to alanines in RGS9-2 is apparently
without effect. In the course of these studies, Martemya-
nov et al. also found that RGS9-2 is a better GAP for
Go than Gi1, as reported previously for RGS9-1 (Hooks
et al., 2003), and found that RGS9-2, like RGS9-1, is an
even better GAP for Gt. Given that Gt and RGS9-2 are
not found in the same cell types, it seems likely that
localization plays a more important role in determining
specificity of action of RGS isoforms on different G pro-
teins than the differences in intrinsic affinity observed.
Important clues to the function of RGS9-2 have come
from behavioral experiments by Eric Nestler and col-
leagues (Rahman et al., 2003 [this issue of Neuron]) that Figure 2. Convergent Regulation of Adenylate Cyclase Activity by
utilize motor activity and reward-seeking as measures Neuromodulators in Medium Spiny Cells of the Striatum
of dopaminergic signaling in the ventral striatum. Viral- D1 and M4 receptors are usually expressed in striatonigral (Sub-
mediated overexpression of either RGS9-1 or RGS9-2 stance P-containing) neurons, whereas D2 and A2A are mostly ex-
pressed in striatopallidal (enkephalin-containing) neurons.isoforms unilaterally in the nucleus accumbens induced
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rhodopsin and transducin are found played an important light of the biochemical evidence presented by Marte-
myanov et al., one might expect that RGS9-1 shouldrole in determining its function. Unfortunately, precise
colocalization in striatal neurons has been difficult be- have lower affinity for its target (presumably Go) than
RGS9-2, at least in the absence of PDE. Perhaps thecause the several antibodies used to great effect with
RGS9-1 suffer from low specificity and affinity when native substrate for RGS9-2 in these cells is normally
a low-affinity interaction, such as that with Gi, whichapplied to RGS9-2 in striatal extracts. Localization is
critical because RGS9-2 presumably must be colo- Martemeyanov et al. found to be relatively insensitive
to both RGS9-1 and RGS9-2. Alternatively, perhaps ancalized with the G proteins and effectors it regulates,
which in turn are likely colocalized with one or more additional molecule in the G protein/effector complex
can serve this affinity adaptor function in the absencespecific GPCR. Moreover, it has been reported that
RGS9-2 and other R7 RGS proteins can be found in the of the C-terminal tail normally present on RGS9-2. A
more mundane explanation may be that the levels ofnucleus, but the role of the nuclear pool in G protein
signaling is unknown. Although RGS9-2 mRNA has been RGS9-1 were sufficiently higher than normal cellular lev-
els of RGS9-2 to act effectively despite its lower basalidentified in medium spiny neurons expressing dopa-
mine D2 receptors, it is also present in an equal fraction activity. The fact that overexpression of RGS4, which
shows robust GTPase activity for both Go and Gi, hadof cells that express D1 receptors (Rahman et al., 2003).
Medium spiny cells can be roughly divided into two no effect suggests that interactions with other proteins,
likely through the non-RGS domains, are important forpopulations, those that contain substance P and primar-
ily express D1, and those that contain enkephalin and RGS9-2 function.
Another puzzle is the role of G5 in the striatum. Striatalprimarily express D2. The expression of RGS9 in both
of these cell types suggests that its function may not neurons express a short version of this protein, G5S,
and although G5S potentiates the effects of RGS9 inbe to regulate D2 receptor signaling per se, but to regu-
late the cascade of some other G protein-coupled recep- vitro, efficacy of RGS9-2, presumably due to GAP activ-
ity, can be observed in the absence of G5S (Kovoor ettor that also regulates adenylate cyclase activity (Figure
2) and is present in both cell populations. al., 2000; Rahman et al., 2003). However, recent results
with G5 knockout mice (Chen et al., 2003) support earlierOn the other hand, the actions of RGS proteins may be
extraordinarily specific for a particular GPCR-coupled proposals that G5 is essential for stable expression of
RGS9 and other R7 family members. It is thus surprisingcascade, particularly if they exist in specific, supramo-
lecular complexes. Indeed, some RGS proteins appear that overexpression of both RGS9 isoforms without si-
multaneous overexpression of G5 has potent effectsto be able to directly regulate GPCRs and effectors
(Druey, 2001). For example, non-R7 RGS proteins such on behavioral responses to drugs. The ability to obtain
overexpression of RGS9-2 and RGS9-1 in the striatumas RGS2 can directly inhibit adenylate cyclase (reviewed
in Kehrl and Sinnarajah, 2002), and an RGS12 isoform may be due to endogenous expression of G5 exceeding
that of RGS9-2, or to some other GGL binding proteindirectly interacts with the C terminus of the interleukin-8
receptor B/CXCR2 in vitro (Snow et al., 1998). Similar compensating for the relative G5 insufficiency.
It is interesting to note that chronic cocaine adminis-receptor-RGS interactions have been proposed for the
R7 family, including RGS9. Current evidence for such tration increased RGS9-2 protein levels (Rahman et al.,
2003), yet had no effect on RGS9 mRNA (Taymans etinteractions for RGS9-2 is indirect and largely based on
the lack of effect of RGS proteins on the steady-state al., 2003; Rahman et al., 2003). This suggests a posttran-
scriptional mechanism can regulate the levels of RGSactivation of GIRK channels in oocyte expression sys-
tems. However, in the present study (Rahman et al., protein in response to agonist exposure. Similarly, in
photoreceptors, disruption of either RGS9 (Chen et al.,2003), coexpression of RGS9-2 with G5S in oocytes did
result in a significant reduction in the steady-state cur- 2000) or G5 (Chen et al., 2003) genes causes a loss of
G5L and RGS9-1 proteins, respectively, without corre-rent amplitude, consistent with the idea that RGS9-2—
which is stabilized by the presence of G5S—acts solely sponding changes in mRNA levels in either case. Thus,
the posttranscriptional regulation of RGS9—and per-by stimulating GTP hydrolysis. Similar effects on the
amplitude of GIRK channels by Go and RGS7 in the haps other RGS proteins—seems an important area for
future study.presence and absence of G5 have also been reported
(Zhang et al., 2002). If indeed D2 activation of Gi/Go is The fact that overexpression or loss of expression of
a single protein that controls G protein deactivation hasregulated by RGS9-2 directly, then other Gi/Go-coupled
pathways (such as signaling through M4 acetylcholine dramatic effects on drug-induced behavior challenges
the notion that dopamine and other neuromodulatorsreceptors) should be unaffected by the loss of RGS9.
Crossing the RGS9 knockouts to existing mice lacking are slow acting. If the purpose of RGS9-2 was simply
to reduce steady-state signaling, changing surface re-various GPCR subtypes will be helpful in determining
this specificity. ceptor expression seems a simpler approach. Instead,
the ability of RGS9-2 to modulate dopamine’s effectsA remaining question involves the functional impor-
tance of RGS9-2’s long C-terminal tail. The biochemical suggests that the cell needs to diminish its response to
dopamine actively. Such rapid and dynamic control ofstudies suggest that activation of RGS9-2 in the striatum
may be constitutive because of the ability of the G protein signaling has precedent; in photoreceptors,
for example, RGS9-1’s action becomes apparent aboutC-terminal extension to supply the activity enhancement
supplied by PDE in the retina. However, RGS9-1, which 100 ms following activation of the receptor protein, rho-
dopsin (Chen et al., 2000). The apparent importance andhas low activity in the absence of PDE, is nearly as
effective in behavioral responses to drug treatment as behavioral relevance of controlling the duration of G
protein signaling suggests that the actual time courseRGS9-2 when ectopically expressed in the striatum. In
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Zhang, Q., Pacheco, M.A., and Doupnik, C.A. (2002). J. Physiol. 545,of G protein signaling in the striatum—and elsewhere in
355–373.the brain—requires closer examination.
Zhong, H., and Neubig, R.R. (2001). J. Pharmacol. Exp. Ther. 297,Although dopamine signaling can be affected by the
837–845.levels of expression of RGS proteins (and vice versa), the
steps linking molecules to behavior remain undefined.
From the present results, it is clear that RGS proteins
play an important role in GPCR modulation of neuronal
signaling in vivo and that this role is specified by com-
plex interactions with multiple proteins and adaptor do-
mains. It therefore seems likely that other members of
the RGS family will also be implicated in temporal regula-
tion of neuronal signaling in other discrete brain regions,
and as such are attractive targets for psychotropic
drugs. A “vertical” approach that merges structure/func-
tion studies like those of Arshavsky with behavioral
assays like those of Nestler, and with combined physio-
logical and molecular studies at the single-cell level, is
needed to determine the specificity with which RGS
proteins regulate G protein signaling in vivo. Integration
of the results from this approach should allow us to
understand how RGS proteins write the spatial and tem-
poral rules by which neuromodulators like dopamine
exert their effects.
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